1.Blonanserin ameliorates phencyclidine-induced visual-recognition memory deficits: the complex mechanism of blonanserin action involving D₃-5-HT₂A and D₁-NMDA receptors in the mPFC.
Hida H1, Mouri A1, Mori K1, Matsumoto Y2, Seki T3, Taniguchi M1, Yamada K4, Iwamoto K5, Ozaki N5, Nabeshima T3, Noda Y1. Neuropsychopharmacology. 2015 Feb;40(3):601-13. doi: 10.1038/npp.2014.207. Epub 2014 Aug 14.
Blonanserin differs from currently used serotonin 5-HT₂A/dopamine-D₂ receptor antagonists in that it exhibits higher affinity for dopamine-D₂/₃ receptors than for serotonin 5-HT₂A receptors. We investigated the involvement of dopamine-D₃ receptors in the effects of blonanserin on cognitive impairment in an animal model of schizophrenia. We also sought to elucidate the molecular mechanism underlying this involvement. Blonanserin, as well as olanzapine, significantly ameliorated phencyclidine (PCP)-induced impairment of visual-recognition memory, as demonstrated by the novel-object recognition test (NORT) and increased extracellular dopamine levels in the medial prefrontal cortex (mPFC). With blonanserin, both of these effects were antagonized by DOI (a serotonin 5-HT₂A receptor agonist) and 7-OH-DPAT (a dopamine-D₃ receptor agonist), whereas the effects of olanzapine were antagonized by DOI but not by 7-OH-DPAT. The ameliorating effect was also antagonized by SCH23390 (a dopamine-D₁ receptor antagonist) and H-89 (a protein kinase A (PKA) inhibitor).
2.Vitamin D deficiency in chronic inflammatory rheumatic diseases: results of the cardiovascular in rheumatology [CARMA] study.
Urruticoechea-Arana A, Martín-Martínez MA, Castañeda S, Piedra CA, González-Juanatey C, Llorca J, Díaz-Gonzalez F, González-Gay MA; CARMA Project Collaborative Group. Arthritis Res Ther. 2015 Aug 14;17:211. doi: 10.1186/s13075-015-0704-4.
INTRODUCTION: The aim was to study the association between 25-hydroxyvitamin D (25(OH)D) levels and the clinical characteristics of patients with chronic inflammatory rheumatic diseases (CIRD).
